COVA322

Home
Ligands
COVA322

GtoPdb Ligand ID: 10469

Comment: COVA322 is a bispecific TNF/IL-17A inhibitor that was designed by Covagen for the treatment of inflammatory diseases including psoriasis, psoriatic arthritis, and rheumatoid arthritis [2]. Structurally COVA322 is a fusion protein containing an antibody that binds to TNF (in this case the light chain of adalimumab) and a Fyn SH3-derived protein (Fynomer) that binds to IL-17A [1]. The fusion protein was produced in transiently transfected Chinese hamster ovary (CHO) cells. COVA322 was able to simultaneously bind TNF and IL-17A.
Clinical development of COVA322 was discontinued due to an unacceptable safety profile that was detected in Phase 1 trial.

No information available.

No information available.

Summary of Clinical Use
COVA322 was advanced to Phase 1a/2b clinical evaluation in patients with stable chronic moderate-to-severe plaque psoriasis. The agent was found to be unsafe and the trial was terminated.

Summary of Clinical Use

COVA322 was advanced to Phase 1a/2b clinical evaluation in patients with stable chronic moderate-to-severe plaque psoriasis. The agent was found to be unsafe and the trial was terminated.

Mechanism Of Action and Pharmacodynamic Effects
Dual TNF/IL-17A inhibition was proposed as a superior mechanism to achieve efficacy in diseases where activation of the pro-inflammatory Th17/IL-17 pathway limits the effectiveness of single agent TNF inhibition.

Mechanism Of Action and Pharmacodynamic Effects

Dual TNF/IL-17A inhibition was proposed as a superior mechanism to achieve efficacy in diseases where activation of the pro-inflammatory Th17/IL-17 pathway limits the effectiveness of single agent TNF inhibition.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT02243787	Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis	Phase 1/Phase 2 Interventional	Covagen